About AVT
Browse Articles
Customer Services

Browse Articles

Additional files for manuscripts published before Volume 14 Issue 6 can be found via the abstract link.

Articles published electronically ahead of print and our archive from Volume 4 Issue 1 to Volume 19 Issue 7 can be found below. Articles published earlier will be made available as soon as possible. If you require an article that cannot be found below, please contact the Editorial Office.

Currently showing:   
Displaying 1862 results:

Original article

Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects

Matt S Anderson, Jocelyn Gilmartin, Caroline Cilissen, Inge De Lepeleire, Luc van Bortel, Marissa Fallon Dockendorf, Ernestina Tetteh, June K Ancona, Rachael Liu, Ying Guo, John A Wagner, Joan R Butterton


Original article

Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV–HCV coinfection

Karin Neukam, Daniela Munteanu, Sebastian Haubitz, José A Mira, Patrick Ingiliz, Antonio Rivero-Juárez, Thomas Lutz, Ignacio de los Santos-Gil, Stefan Scholten, Manuel Márquez, Andri Rauch, Jürgen K Rockstroh, Juan A Pineda


Original article

Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single-arm study

Akira Watanabe, Phillip J Yates, Marie Murayama, Toru Soutome, Hiroiku Furukawa


Original article

Baseline CD4+ T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients

Nicoletta Ciccarelli, Pierfrancesco Grima, Massimiliano Fabbiani, Eleonora Baldonero, Alberto Borghetti, Benedetta Milanini, Silio Limiti, Manuela Colafigli, Enrica Tamburrini, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto


Original article

Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility

Massimiliano Fabbiani, Pierfrancesco Grima, Benedetta Milanini, Annalisa Mondi, Eleonora Baldonero, Nicoletta Ciccarelli, Roberto Cauda, Maria C Silveri, Andrea De Luca, Simona Di Giambenedetto



Very late HCV relapse following triple therapy for hepatitis C

Pablo Barreiro, Eugenia Vispo, Ivana Maida, Antonio Aguilera, José V Fernández-Montero, Carmen de Mendoza, Pablo Labarga, Vincent Soriano

Antiviral Therapy 2014; 19:723-724


The impact of wild-type reversion on transmitted resistance surveillance

David C Boettiger, Sasisopin Kiertiburanakul, Somnuek Sungkanuparph, Matthew G Law, the TREAT Asia Studies to Evaluate Resistance

Antiviral Therapy 2014; 19:719-722

Workshop report

Summary of presentations from the International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge, 3–7 June 2014, Berlin, Germany

Neil Parkin

Antiviral Therapy 2014; 19:701-717

Short communication

Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: The CASTLE biomarker substudy

Graeme Moyle, Helene Hardy, Jonathan Uy, Neelanjana Ray, Maria Jesus Jimenez-Exposito, Donnie McGrath, Edwin DeJesus

Antiviral Therapy 2014; 19:693-699

Short communication

Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity

Rujuta A Bam, Stephen R Yant, Tomas Cihlar

Antiviral Therapy 2014; 19:687-692

Copyright © Nucleus Global 2014. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.